Phase Ib study investigating whether liposome BLP25 mucin-1 (MUC1) peptide-specific
immunotherapy (L-BLP25) administered as weekly subcutaneous doses over 8 weeks following a
single dose of intravenous cyclophosphamide (CPA) induces a reproducible cytokine pattern
measured in the serum of unresected Stage III non-small cell lung cancer (NSCLC) subjects
after first-line chemo-radiation therapy.